Cord Dohrmann

Biography

Dr Cord Dohrmann (born in 1964) joined Evotec AG as Chief Scientific Officer and Member of the Management Board on 01 September 2010. Dr Dohrmann has spent over 20 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the Max-Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company with a pipeline of highly innovative preclinical and clinical products for the treatment of diabetes and related disorders. Dr. Dohrmann has been advising the European Commission, the Max-Planck-Institute as well as venture capital firms and authored and co-authored a number of publications and patents. Since December 2016, Dr Cord Dohrmann has been serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, Dr Cord Dohrmann became a member of the Supervisory Board of Facio Therapies BV.  

Research Interest

 Dr Cord Dohrmann has research interest in Biomedical Science, Developmental Biology and Busines management.